When serum sample was obtained, patients with active uveitis associated with BD were receiving the following therapies: 3/13 patients were not receiving any immunomodulatory treatment (naïve subjects with first episode of uveitis attack), 7/13 were treated with BRM (TNF-α antagonists), 2/13 were receiving CS, and 1/13 was receiving conventional IS therapy. This evidence concerns the gene TNF and uveitis.